



Folia Biologica et Oecologica  13: 1–8 (2017) 



























Tumor necrosis factor alpha (TNF- α) 
as an example of cytokine 
Cytokines are broad and small 
proteins, molecules and hormone-like 
proteins (5-20kDa) (Badowska-
Kozakiewicz 2013) playing an extremely 
important role in many cellular processes, 
such as growth, differentiation, migration, 
and apoptosis. They also play an 
important role in immune reactions, 
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ABSTRACT 
The inflammatory process is directly associated with secretion of cytokines, 
e.g. tumor necrosis factor alpha (TNF-α). This molecule is one of the 22 
proteins which belong to TNF family and is secreted mainly by: 
macrophages, monocytes, T lymphocyte and mast cells. The biological 
effects of TNF-α is possible through binding this cytokine to specific 
receptors – TNFR1 and TNFR2. The large number of reports provides that 
this cytokine plays extremely important role in cancers and cardiovascular 
disease – two groups of inflammatory diseases. Unfortunately, these 
diseases are the main cause of death in spite of  advances in medicine and 
increasing public awareness of prevention. 
It is believed that better understanding both molecular potential of this 
cytokine and the impact in cancerogenesis and others inflammatory diseases 
may cause using TNF-α as a molecular marker in these diseases and will 
make it possible to observe the effects of anti-inflammatory therapy. It will 
be able to cause a drop in the incidence of these diseases and better 
monitoring of them. 
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inflammatory processes, maintenance of 
tissue homeostasis. Cytokines can cause 
pyrogenic effects on energy balance of the 
body due to the change of appetite, impact 
both on the structure and functioning  
of the cardiovascular system or the 
regulation of activity of the autonomic 
nervous system. The biological effects of 
cytokines are possible because they are 
important mediators of signaling 
pathways (Chechlińska 2003, Commins et 
al. 2010).  
The family of cytokines includes: 
chemokines, interferons, interleukins, 
lymphokines and tumor necrosis factors. 
These molecules are produced by 
different kinds of cells, for example: 
active immune cells, keratinocytes, 
cardiomyocytes, myocytes, fibroblasts, 
neurons and glial cells. The characteristic 
feature of the cytokines is the fact that 
they have pleiotropic, often opposing 
activity depending on both the type of cell 
by which they are secreted and acting 
(Ufnał & Wołynczyk-Gmaj 2003). This 
fact can cause a problem with 
classification of cytokines but generally it 
is carried out on the basis of pro- and anti-
inflammatory effects (Bergler-Czop & 
Brzezińska-Wcisło 2011). 
 
The characterization of tumor necrosis 
factor alpha (TNF- α) 
One of the best characterized cytokine 
is a tumor necrosis factor alpha (TNF-α) 
which is known also as a cachectin or 
differentiation-inducing factor (DIF) and 
secreted mostly by: monocytes, 
macrophages, T lymphocytes and mast 
cells. It is a pro-inflammatory cytokine 
and one of the 22 proteins which belong 
to the TNF family (Badowska-
Kozakiewicz 2013). The gene encoding 
this compound is built with 4 exons and is 
relatively small (3kbp) compared to genes 
encoding, for example: interleukin 1β (31 
kbp) or isoform 1 of cyclooxygenase (22 
kbp) and isoform 2 of this enzyme (8.3 
kbp) (Korobowicz 2006). 
Polymorphisms in the promoter region 
of the TNF-α gene play an extremely 
important role because they regulate the 
transcriptional activity of this cytokine 
and also have an influence on the 
biological activity. The best known  
TNF-α polymorphism is biallelic 
polymorphism -308G / A. The allele -
308A is associated with increasing 
transcriptional activity of the TNF-α gene 
in vitro and synthesis of greater amounts 
in vivo than the allele -308G. Other 
polymorphisms having the ability to 
modulate gene expression of TNF-α are: -
238G / A, -865C / A, -859G / A, -1032T / 
C (Kocierz et al. 2007). 
  
The role of TNF- α and its receptors in 
transduction of molecular signals 
This proinflammatory cytokine is 
present in two forms. First is a membrane 
(precursor) form with a molecular weight 
of 26 kDa and second is a 17 kDa 
secretory form after the enzyme 
modification (Korobowicz 2006, 
Horiuchi et al. 2013).  
The result of the translation process is 
26 kDa precursor form, called the 
transmembrane TNF-α (tmTNF-α). It is 
modified involving metalloproteinase 
enzyme TACE (TNF-α-converting 
enzyme, EC3.4.24), resulting in cutting 
off 76 N-terminal amino acids and making 
biologically active form of the cytokine - 
sTNF-α (soluble TNF-α, 17 kDa). Both 
forms are homotrimers capable to interact 
with receptors (Juszczyński & Warzocha 
2002, Horiuchi et al. 2013). 
There are evidences that both forms  
of TNF-α - soluble and precursors, 
participate in the inflammatory response. 
They also indicate that tmTNF-α may act 
as a bipolar molecule transducing the 
signal, as a ligand by attaching to 
receptors of TNF-α or as a receptor for 
transmitting signals to cells producing 
TNF-α. Transmembrane form of TNF-α is 
capable of binding to both receptors - 
TNFR1 and TNFR2, but it seems that the 
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signaling pathway with the participation 
of TNF-α anchored in the membrane is 
initiated by receptor-2 (Horiuchi et al. 
2013). 
The biological changes caused by 
TNF-α still remain not fully explained, 
however it is known that these changes 
occur via two receptors for this cytokine – 
TNFR1 and TNFR2 and it will help to 
understand the transduction of the 
molecular signal. There are two types  
of this receptors – transmembrane 
(tmTNFR1 and tmTNFR2) and soluble 
form (sTNFR1 and sTNFR2) (Wcisło et 
al. 2002, Badowska-Kozakiewicz 
2013).TNFR1 is expressed on the surface 
of most nucleated cells while TNFR2 only 
on the surface of  immune cells.  
Transmembrane form of TNFR1 and 
TNFR2 are built by three domains – ECD 
(extracellular domain), TMD 
(transmembrane domain) and ICD 
(intracellular domain) (Korobowicz 
2006). The soluble form is built only by 
ECD domain and is formed by proteolytic 
hydrolysis of the extracellular domain of 
immune cells, particularly monocytes and 
macrophages. There are evidences that 
sTNFR1 and sTNFR2 are present in the 
cerebrospinal fluid – spinal, tissues with 
difficulty of draining the lymph (Serwin et 
al. 2004). Soluble receptors play an 
important role in the processes associated 
with the modulation of the immune 
response. In addition, they are involved in 
the binding and inactivation of TNF-α, 
contributing to the modification of the 
activation of programmed cell death 
(Mielczarek et al. 2011). Increased 
expression and elevated plasma 
concentrations of both forms of the 
soluble receptors for TNF-α are observed 
in obesity. However, sTNFR1 has the 
greatest influence on the development of 
obesity and responds to insulin resistance, 
increasing energy expenditure and in 
consequence reducing the body weight 
(Olszaniecka-Glianowicz 2005, Goral 
2008, Szalecki et al. 2008). 
The signaling pathways of TNF-α 
cause two different effects: cell death 
(mainly by TNFR1 which has death 
domain associated with ECD) or 
activating NF-κB signal transduction 
leading to cells survival (Krzyżowska et 
al. 2009, Szołtysek et al. 2011, Skórka & 
Giannopoulos 2012). It can be observed 
that signaling pathway of this cytokine is 
a complex process. 
 
Cancers and cardiovascular disease as 
a global health problems 
The cancers and cardiovascular 
diseases are two main death causes. The 
World Health Organization's (WHO) 
statistical analysis shows that in 2008, 30 
percent of all global deaths were 
associated with cardiovascular disease 
and this number has been increasing. Data 
collected by WHO highlights also that 
„cancer is a leading cause of death 
worldwide, accounting for 8.2 million 
deaths in 2012” (www.who.int). 
According to these data cancer and 
cardiovascular diseases are very serious 
global problem despite advances in 
medicine and increasing public awareness 
of prevention. Therefore, besides better 
understanding of the mechanisms 
associated with the disease, it would be 
important to find a complementary 
diagnostic molecular marker, which may 
be TNF-α. TNF-α is called a „new marker 
of inflammatory process” (Będowska 
2007, Kabłak-Ziemnicka 2010). 
 
TNF-α as a molecular marker in 
diseases 
Some reports show that TNF-α is 
useful as a potential marker. Kacperska et 
al. noted that changes in serum 
concentration of TNF-α may be a 
potential marker in multiple sclerosis 
(MS) which is an inflammatory and 
neurodegenerative disease (Kacperska et 
al. 2014). The possibilities of using this 
cytokine as a marker were observed in 
inflammatory bowel disease (IBD) 
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although some reports show the opposite 
information (Eder et al. 2007). In spite of 
these discrepancies, Komatsu et al. 
provided a higher concentration of TNF-α 
in serum of patients with IBD, 
recommending to analyse the changes 
using immuno-PCR, which is more 
sensitive than ELISA method (Komatsu et 
al. 2001). Olczyk-Kwiecień et al. 
observed that patients with rheumatoid 
arthritis treated aggressively had low 
levels of TNF in serum what confirmed 
the role of this cytokine in inflammatory 
process (Olczyk-Kwiecień et al. 2006).  
The figure 1 shows the changes in 
level of TNF-α in serum of patients with 
cancers and cardiovascular diseases. It 
can be observed that during these 
processes this cytokine is secreted with 
higher amounts compared to control 
(healthy people). The graph shows the 
wide variation in specific tumor types 
(from 1.5 pg/ml in the breast cancer to 
22.1 pg/ml in the pancreatic cancer). 
According to this results it can be 
observed that cardiovascular diseases and 
cancers are pro-inflammatory diseases of 
the substrate, accompanied by increased 
secretion of inflammatory agents 
including TNF-α (Scheen-Chen et al. 
1997, Kapadia et al. 2000, Gasiorowska et 
al. 2016). 
Figure 1. The level of TNF-α in different cancers and types of cardiovascular diseases and control. This chart 
was based on data from: Scheen-Chen et al. 1997, Kapadia et al. 2000, Gasiorowska et al. 2016. 
 
 
TNF- α in cancer and cancerogenesis  
TNF-α in carcinogenesis has two 
opposite ways of action. On the one hand 
it inhibits the proliferation of tumor cells 
and increases apoptosis of this kind of 
cells although it can promote metastasis 
by influencing the synthesis and activity 
of matrix metalloproteinases. TNFR1 is 
responsible for cytotoxicity of tumor 
necrosis factors against tumor cells. In 
contrast, TNFR2 is responsible for effects 
of the acute phase (Wolańska et al. 2010). 
It was observed that the synthesis  
of small amounts of TNF-α in  
the tumor microenvironment, promoting 
development of tumor growth as well as 
the surrounding cells, induces apoptosis. 
However, the higher amounts initiate 
tumor cell death and stimulate the 
antitumor response (Tse et al. 2012). It is 
believed that chronic inflammation is one 
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of the main risk factors for the 
development of carcinogenesis process, in 
which TNF-α plays an extremely 
important role. It is involved in all aspects 
of the carcinogenesis: transformation, 
proliferation, angiogenesis and metastasis 
(Wang & Lin 2008). The antitumor effect 
of TNF-α is associated with modulation of 
immune response and leads to instant 
destruction of tumor stroma by cytotoxic 
T lymphocyte or activation of dendritic 
cells. 
The reports show the higher level of 
this pro-inflammatory cytokine in the 
serum of patients with various types of 
cancers. Furthermore, the transcriptional 
activity of TNF-α increases in 
precancerous stages and is a negative 
prognostic indicator of tumor 
development (Wang & Lin 2008). 
TNF-α exhibits a devastating effect on 
tumor vessels, including by changing the 
properties of endothelial cells from 
anticoagulant to procoagulant leads to 
stimulation of tissue factor expression  
and inhibition of thrombomodulin 
(Juszczyński & Warzocha 2002). NF-κB 
stimulated by TNF-α  has the opposite 
effect, anti-tumorigenic in the organ that 
regenerates itself rapidly (liver) cells and 
pro- tumorigenic in colon, which 
regenerates slowly (Wang & Lin 2008). 
The data analysis provide ambivalent 
effect of TNF-α on cancerogenesis, which 
can be a problem with the use of this 
cytokine as a marker. Despite this fact, 
some reports show possibilities of using 
this agent to observe and diagnose the 
process associated with cancerogenesis. 
 
The role of TNF-α in cardiovascular 
diseases  
In hypertension, which is one example 
of cardiovascular disease there is an 
increase in level of pro-inflammatory 
cytokines in the blood and tissues of the 
cardiovascular system (Ufnał & 
Wołynczyk-Gmaj 2011). The studies have 
confirmed the higher serum levels of 
many pro-inflammatory proteins, for 
example: CRP, IL-6, IL-8, TNF-α in 
patients with hypertension (Głuszek & 
Kosicak 2011). It is believed that TNF-α 
and other cytokines produced in large 
amounts are the main factors responsible 
for the progress and development of heart 
failure. Depending on the concentration, 
TNF-α exerts protective or harmful effect 
on the cell function of the heart and 
myocardium. Low levels of this cytokine 
is associated with a protective effect 
(Kurrelmeyer et al. 2000), while the 
higher leads to toxic effect on the 
myocardium, for example: dysfunction 
and remodeling of left ventricular, 
myocardial metabolism disorder, 
intensification of oxidative stress and 
endothelial dysfunction. Otherwise 
activating sphingomyelinase exacerbates 
the apoptosis of cardiomyocytes 
(Agnoletti et al. 1999). 
TNF-α is involved in the production of 
other pro-inflammatory cytokines, i.e. IL-
1, IL-6, which in turn increases metabolic 
disorders associated with myocardial 
infarction (Puszkarska & Głuszek 2010, 
Głuszek & Kosicak 2011). TNF-α is one 
of the most important cytokine 
responsible for the endothelial 
dysfunction, which is characteristic of 
hypertension (Pacholczyk et al. 2008). 
The mechanism occurring in this process 
is the activation of NF- κB, which by 
binding to the promoter sequence of the 
genes that encode cell adhesion 
molecules: VCAM-1, ICAM-1, MPC-1, 
E-selectin in endothelial cells and 
vascular smooth muscle cells increases 
their expression (Ouchi et al. 1999). TNF-
α is also responsible for the damage to the 
integrity of the endothelial cells by 
induction of apoptosis of these cells 
(Hermann et al. 2000). 
 
Summary 
The large number of reports shows 
that TNF-α is directly associated with 
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inflammatory process, cancer and 
cardiovascular disease. It is extremely 
important to better understand the 
mechanisms and signaling pathways of 
TNF-α to use this cytokine as a molecular 
marker of pro-inflammatory diseases. 
This action will be useful in thediagnosis 
and treatment of cancers and 
cardiovascular diseases. 
The studies and statistical data show 
how cancer and cardiovascular diseases 
are a serious problem and highlight the 
need to find new diagnostic marker. TNF-
α can be used as a potential marker, which 
was confirmed in a large number of 
reports, however a better understanding of 
the biological role of this cytokine is 
absolutely essential. 
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Proces zapalny jest bezpośrednio związany z sekrecją cytokin, np. czynnika 
martwicy nowotworu alfa (ang. Tumor Necrosis Factor alpha; TNF-α). Ta cząsteczka 
jest 1 z 22 białek należących do rodziny TNF i wydzielana jest głównie przez: makrofagi, 
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monocyty, limfocyty T oraz komórki tuczne. Biologiczne efekty działania TNF-α 
zachodzą dzięki wiązaniu się tej cytokiny ze specyficznymi dla niej receptorami – 
TNFR1 i TNFR2. Duża liczba prac potwierdza kluczową rolę TNF-α w nowotworzeniu 
i chorobach układu sercowo-naczyniowego, będących chorobami o podłożu 
prozapalnym. Niestety, mimo postępu medycyny i wzrostu świadomości społeczeństwa, 
wymienione choroby stanowią główne przyczyny śmierci na świecie. Lepsze 
zrozumienie roli tej cytokiny w kancerogenezie i chorobach zapalnych może 
spowodować wykorzystanie TNF-α jako markera tych chorób oraz do  monitorowania  
przeciwzapalnych efektów terapii.   
 
